Quantbot Technologies LP Sells 97,191 Shares of Bausch Health Companies Inc. (NYSE:BHC)

Quantbot Technologies LP reduced its position in shares of Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 95.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,352 shares of the company's stock after selling 97,191 shares during the quarter. Quantbot Technologies LP's holdings in Bausch Health Companies were worth $35,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in BHC. Northwest & Ethical Investments L.P. increased its stake in shares of Bausch Health Companies by 119.7% during the fourth quarter. Northwest & Ethical Investments L.P. now owns 71,139 shares of the company's stock valued at $574,000 after buying an additional 38,755 shares during the period. Magnetar Financial LLC purchased a new position in Bausch Health Companies during the 4th quarter valued at $151,000. Intact Investment Management Inc. raised its holdings in Bausch Health Companies by 38.3% in the 4th quarter. Intact Investment Management Inc. now owns 261,300 shares of the company's stock worth $2,112,000 after purchasing an additional 72,300 shares in the last quarter. Kendall Capital Management lifted its position in shares of Bausch Health Companies by 43.4% in the 4th quarter. Kendall Capital Management now owns 17,995 shares of the company's stock worth $145,000 after purchasing an additional 5,445 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in shares of Bausch Health Companies during the 4th quarter valued at about $180,000. Hedge funds and other institutional investors own 78.65% of the company's stock.

Remove Ads

Bausch Health Companies Stock Performance

Shares of Bausch Health Companies stock traded down $0.34 during midday trading on Friday, hitting $5.34. The company had a trading volume of 3,167,842 shares, compared to its average volume of 2,732,458. The company has a 50 day moving average of $6.91 and a 200 day moving average of $7.69. The stock has a market capitalization of $1.96 billion, a P/E ratio of -44.45, a P/E/G ratio of 0.37 and a beta of 0.43. Bausch Health Companies Inc. has a 52-week low of $3.96 and a 52-week high of $10.46.

Bausch Health Companies (NYSE:BHC - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.44). The company had revenue of $2.56 billion for the quarter, compared to the consensus estimate of $2.51 billion. Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. Equities research analysts forecast that Bausch Health Companies Inc. will post 4.41 EPS for the current year.

Analyst Ratings Changes

BHC has been the subject of several research analyst reports. Jefferies Financial Group restated a "hold" rating and issued a $8.00 price objective (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. Royal Bank of Canada lowered their target price on Bausch Health Companies from $11.00 to $10.00 and set a "sector perform" rating for the company in a research note on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company's stock. According to data from MarketBeat, Bausch Health Companies presently has a consensus rating of "Hold" and an average price target of $7.42.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.